USANA Health Sciences initiated with "outperform"

09/25/06 - Ryan, Beck & Co

NEW YORK, September 25 (newratings.com) - Analyst Mark Rupe of Ryan Beck & Co initiates coverage of USANA Health Sciences (USNA) with an "outperform" rating. The target price is set to $52.

In a research note published this morning, the analyst mentions that the company has posted robust 2Q sales. USANA Health Sciences has the potential to post revenues and EPS growth of 15% and 15-20% annually in the forthcoming several years, the analyst adds. The company has issued robust sales and EPS growth guidance for 2006 of 15%-17% and 17%-20%, respectively.